CJC-1295 no-DAC 5mg

CJC-1295 No DAC is a modified Growth Hormone-Releasing Hormone (GHRH) analog. Unlike CJC-1295 with DAC, the 'no DAC' version has a significantly shorter half-life. This design choice results in more frequent yet physiologically pulsatile secretion of growth hormone (GH) when administered to research models.

Mechanism of Action

CJC-1295 No DAC acts as a GHRH analog, binding to GHRH receptors in the anterior pituitary gland. This binding stimulates the natural pulsatile release of growth hormone from the pituitary. Because it does not contain the Drug Affinity Complex (DAC), it is rapidly cleared from the system, mimicking the body's natural intermittent release patterns of GHRH more closely than the DAC variant. This characteristic makes it suitable for research aiming to understand the effects of more naturalistic GH pulsatility.

Structure and Class

CJC-1295 No DAC is a 29-amino acid peptide, structurally similar to the N-terminal fragment of naturally occurring GHRH, specifically GHRH(1-29). The key modification lies in the absence of DAC, which in other variants, extends the half-life by binding to albumin. This absence ensures a shorter duration of action, positioning it within the class of GHRH secretagogues that induce acute, rather than sustained, GH release.

Primary Research Areas

Investigational research with CJC-1295 No DAC primarily focuses on its potential to study growth hormone regulation and its physiological roles. Researchers explore its effects on lean body mass, metabolic processes, and overall systemic functions in various research models. It is often co-administered with Growth Hormone-Releasing Peptides (GHRPs) like Ipamorelin to achieve synergistic increases in GH secretion for more robust research outcomes.

Notable Peer-Reviewed Findings

Early research indicated that CJC-1295 could induce a sustained increase in IGF-1 and GH levels in animals, although these findings were often related to the DAC-modified version. For CJC-1295 No DAC, studies highlight its role in promoting a more natural, pulsatile release of GH, avoiding the continuous GH elevation seen with longer-acting analogues. This pulsatile pattern is considered important for maintaining pituitary sensitivity and preventing negative feedback mechanisms in research models, suggesting its utility in studies exploring physiological GH dynamics where intermittent signaling is desired.